|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum free light chain escape in progression and treatment resistance in multiple myeloma: a marker for the impact of intra-clonal heterogeneity 显示文摘 | Brioli A Campbell JP Kaiser MF | 2013 | Blood (ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 2 | Multiple myeloma, venous thromboembolism,and treatment-related risk of thrombosis显示文摘 | Zamagni E Brioli A Tacchetti P | 2011 | Semin Thromb Hemost2011，37，3： | 1 |
| 3 | The utility of newer imaging techniques as predictors of clinical outcomes in multi- ple myeloma 显示文摘 | Brioli A Morgan GJ Durie B | 2014 | Expert Rev Hematol2014，7，1： | 1 |
| 4 | Multiple myeloma, venous thromboembolism,and treatment-related risk of thrombosis 显示文摘 | Zamagni E Brioli A Tacchetti P | 2011 | Semin Thmmb Hemost2011，37，3： | 1 |
| 5 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma显示文摘 | Michele Cavo Lucia Pantani Maria Teresa Petrucci Francesca Patriarca Elena Zamagni Daniela Donnarumma Claudia Crippa Mario Boccadoro Giulia Perrone Antonietta Falcone Chiara Nozzoli Renato Zambello Luciano Masini Anna Furlan Annamaria Brioli Daniele Derud | 2012 | Blood2012，，1： | 1 |
| 6 | Contrast enhanced MRI and 18F - FDG PET - CT in the assessment of multiple myeloma:A com- parison of results in different phases of the disease显示文摘 | Spinnato P Bazzocehi A Brioli A | 2012 | Enr J Radiol2012，81，12： | 1 |
| 7 | Multiple myeloma, venous thromboembolism, and treatment-related risk of throm- bosis显示文摘 | Zamagni E Brioli A Tacchetti P | 2011 | Semin Thromb Hemost2011，37，3： | 1 |
| 8 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma显示文摘 | Michele Cavo Lucia Pantani Maria Teresa Petrucci Francesca Patriarca Elena Zamagni Daniela Donnarumma Claudia Crippa Mario Boccadoro Giulia Perrone Antonietta Falcone Chiara Nozzoli Renato Zambello Luciano Masini Anna Furlan Annamaria Brioli Daniele Derud | 2012 | Blood2012，，1： | 1 |
| 9 | Contrast enhanced MRI and18F-FDG PET-CT in the assessment of multiple myeloma:a comparison of results in different phases of the disease显示文摘 | Spinnato P Bazzocchi A Brioli A | 2012 | Eur J Radiol2012，81，： | 1 |
| 10 | Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma显示文摘 | Borsi E Terragna C Brioli A | 2015 | TranslRes2015，65，6： | 1 |
| 11 | Multiple myeloma,venous thromboembolism,and treatment-related risk of thrombosis显示文摘 | Zamagni E Brioli A Tacchetti P | 2011 | Semin Thromb Hemost2011，37，3： | 1 |
| 12 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis 显示文摘 | Zamagni E Brioli A Tacchetti P | 2011 | Semin Thromb Hemost2011，37，3： | 1 |
| 13 | Contrast enhanced MRI and 18 F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease显示文摘 | P. Spinnato A. Bazzocchi A. Brioli C. Nanni E. Zamagni U. Albisinni M. Cavo S. Fanti G. Battista E. Salizzoni | 2012 | European Journal of Radiology2012，，12： | 1 |
| 14 | First line vs delayed transplantation in myeloma:Certainties and controversies显示文摘Since the middle of 1990 s autologous stem cell trans-plantation has been the cornerstone for the treatment of young patients with multiple myeloma(MM). In the last decade the introduction of novel agents such as immunomodulatory drugs(IMi Ds) and proteasome inhibitors(PI), has dramatically changed the therapeutic scenario of this yet incurable disease. Due to the impressive results achieved with IMi Ds and PI both in terms of response rates and in terms of progression free and overall survival, and to the toxicity linked to high dose therapy and autologous stem cell transplantation(ASCT), a burning question nowadays is whether all young patients should be offered autotransplanta-tion up front or if this should be reserved for the time of relapse. This article provides a review of the data available regarding ASCT in MM and of the current opinion of the scientific community regarding its optimal timing. | Annamaria Brioli | 2016 | World Journal of Transplantation2016，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员